EDC for investigator-initiated trials: lean teams, budget-sensitive pricing, and 21 CFR Part 11–aligned controls in one platform.
21 CFR Part 11–aligned · HIPAA-aligned security · No credit card required
Many IIT investigators are familiar with REDCap, and some may wonder why they should consider an alternative. REDCap serves an important role in academic research, particularly for surveys, data registries, and studies where electronic signature and comprehensive audit trail requirements are not critical. However, for investigator-initiated clinical trials—especially those that involve interventional protocols, informed consent documentation, or data that may support regulatory submissions—REDCap has limitations that Capture addresses. Capture provides integrated eConsent with digital signature capture, consent versioning, and PDF export—features that meet the documentation expectations for clinical trial informed consent. The audit trail in Capture is designed with 21 CFR Part 11–aligned controls, logging every data entry, modification, and signature with timestamps and user attribution. Role-based access distinguishes between investigators, coordinators, monitors, and data managers with appropriate permissions. And ePRO is integrated as a native module rather than a workaround. For IIT investigators who need clinical-trial-grade data capture with the simplicity of an academic tool, Capture provides a practical middle ground: purpose-built for clinical research, accessible without enterprise overhead, and compliant with the standards that IRBs, sponsors, and regulators expect.
For grant-funded IITs, the EDC budget line item must be justified to the funding agency and fit within the overall study budget. Enterprise EDC platforms with per-site fees, per-patient charges, and multi-year licensing requirements can be difficult to budget accurately in a grant application, and may represent a disproportionate share of the total study cost. Capture’s pricing model is designed for IIT budget structures. The free Sandbox tier allows investigators to build and test their study design during the grant application or pre-award phase, before any budget is committed. Live Studies and Enterprise plans scale with study size, so the EDC cost is proportional to the study’s scope. There are no per-site fees or enterprise minimums that create budget misalignment for small investigator-led studies. For grant applications, the EDC cost can be included as a direct cost in the "Other" or "Equipment/Software" budget category. Some institutions may also support EDC costs through research infrastructure or shared resource mechanisms. The predictable pricing model makes it straightforward to budget in NIH, NSF, foundation, or institutional grant applications.
Many IITs generate preliminary data that leads to industry interest—a pharma or biotech company may want to license the approach, co-develop the program, or sponsor a larger follow-on trial. When this transition occurs, the industry partner will evaluate the quality and integrity of the IIT data as part of their due diligence. Data captured in a compliant EDC system with comprehensive audit trails and electronic consent documentation provides a stronger foundation for these discussions than data from spreadsheets or tools without clinical-trial-grade controls. Capture positions IIT data for this transition by providing 21 CFR Part 11–aligned controls from the start. The audit trail documents data provenance from enrollment through database lock. Electronic consent records demonstrate that participants provided informed agreement. And structured data exports provide the industry partner with analysis-ready datasets that meet their expectations for data quality. This forward-looking approach to data capture does not require additional effort at the IIT stage—it is simply a consequence of using a compliant platform from the beginning. But when an industry partner expresses interest, the PI can present data with confidence that it meets the standards expected for clinical trial data.
Overview
Investigator-initiated trials (IITs) are clinical studies conceived, designed, and led by investigators or institutions rather than industry sponsors. IITs are the engine of academic medicine and translational research: they test novel hypotheses, explore off-label uses, conduct comparative effectiveness research, and generate the preliminary data that informs larger industry-sponsored programs. They represent a significant share of all clinical trials, particularly in academic medical centers and university hospitals. IITs operate under a distinct set of constraints. The principal investigator (PI) serves as both the scientific lead and the sponsor, bearing responsibility for regulatory compliance, data integrity, and study operations. Budgets are typically grant-funded (NIH, NSF, foundation, or institutional) with fixed timelines and limited flexibility. Study teams are lean—often a PI, one or two coordinators, and a part-time data manager. And the PI must balance the demands of running the trial with their clinical, teaching, and research responsibilities. Despite these constraints, IITs carry the same regulatory expectations as industry-sponsored trials when it comes to data integrity. IRBs require documented informed consent with appropriate audit trails. When IIT data supports an IND or regulatory submission, 21 CFR Part 11–aligned controls are expected. And when results are published, peer reviewers and journal editors evaluate whether data was captured with appropriate rigor. Capture provides EDC, eConsent, ePRO, and safety in one platform with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure. The platform is designed for investigator-led studies: rapid build without vendor dependency, a free Sandbox tier for study design and testing, pricing that fits grant budgets, and one integrated system that lean IIT teams can operate without dedicated IT staff.
IITs face a specific gap in the clinical trial software market. Enterprise EDC platforms are designed for industry sponsors with large budgets, dedicated clinical operations teams, and multi-month implementation timelines. These platforms are often priced per site, per patient, or per module—models that do not align with grant-funded IIT budgets. Implementation timelines of 3–6 months can consume a significant portion of a 2–3 year grant period before the first participant is enrolled. At the other end, many IIT investigators turn to REDCap or similar academic tools because they are free and familiar. While these tools serve certain academic research needs, they have limitations in areas that matter for clinical trials: electronic signature workflows for consent, comprehensive audit trails that meet 21 CFR Part 11 expectations, role-based access controls that distinguish between coordinators, investigators, and monitors, and structured data export for regulatory use. Capture bridges this gap by providing a purpose-built clinical trial platform with compliance controls that meet regulatory expectations, at a price point and deployment model that fits IIT operations. The free Sandbox tier allows investigators to build and test their study design before committing any budget. Configuration-driven study build means the PI’s team can set up CRFs, consent forms, and ePRO questionnaires through the browser without requiring programming or vendor support.
FAQ
Explore the platform with a free sandbox. No sales call required.